Back

ATTRibute-CM: ITT sensitivity analysis and sub-analysis comparing acoramidis and placebo in stage 4 CKD

11 May 2024 (15:18 - 15:27)
Organised by: Logo
Congress Presentation Part of: Cardiomyopathies: present and future Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Steen Hvitfeldt Poulsen

Aarhus University Hospital, Aarhus N (Denmark)

4 More presentations in this session

Presentation thumbnail
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis
Doctor R. Rettl (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Temporality of events leading to the diagnosis of obstructive hypertrophic cardiomyopathy (oHCM): a machine learning approach using UK retrospective data
Mr M. Hurst (Cardiff, GB)
Abstract Slides Video
Presentation thumbnail
Delayed diagnosis of hypertrophic cardiomyopathy: results from electronic medical records analysis
Doctor C. Mao (San Francisco, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathies: present and future
Video

The Event

Event poster

Heart Failure 2024

11 May 2024 15:18 CET
You may be interested in
thumbnail
Congress Presentation
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
thumbnail
Congress Presentation
Discussant review - ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources